June 3, 2019
AlphaBiomics featured as one of the 2019 residents of JLABS @ BE
AlphaBiomics is featured in this article by Labiotech.eu as one of seven companies who joined JLABS @ BE in 2019. It is the first JLABS incubator in Europe and located on the Janssen Pharmaceutica R&D Campus in Beerse, Belgium. JLABS will provide a stimulating, creative, scientific and commercial environment as well as an opportunity to network.
May 8-9, 2019
AlphaBiomics pitched at State of the Union event in Ghent, BE
AlphaBiomics was among four start-up companies to pitch at the 5th edition of the State of the Union event in Ghent, Belgium. This event was held the evening before the annual knowledge for growth conference which we also attended. Both gatherings are organised annually by flanders.bio, a life sciences cluster organisation based in Flanders, Belgium. Positive feedback on the pitch and great networking opportunities at both events led to many new contacts.
April 10-11, 2019
AlphaBiomics at the Diagnostics North East Conference 2019
AlphaBiomics has attended a Dx-focused workshop and conference organised by Diagnostics North East. We heard from experts in the Dx field and made valuable connections.
March 6-9, 2019
AlphaBiomics at the 14th Congress of ECCO
AlphaBiomics is attending the 2019 congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. We are looking forward to hear the latest in IBD research and treatment and to catch up with old and meet new collaborators. Busy 3 days ahead!
February 5, 2019
AlphaBiomics wins award to advance its platform
AlphaBiomics has been awarded an Invention for Innovation (i4i) Connect grant to complete its pioneering microbiome analysis platform, ABFlow+. This project is funded by the National Institute for Health Research (NIHR) i4i Connect NIHR200405. Working with renowned experts, AlphaBiomics will develop and validate computationally and statistically robust toolkits for AI-based analysis of microbiome-derived data sets. The funds will also allow AlphaBiomics to perform health economic modelling for its precision medicine products and to engage relevant stakeholders including patients, healthcare professionals, and payors. This award enables AlphaBiomics to progress its discovery program and to advance its mission of bringing safer and more efficacious drug therapies to patients.
January 29-30, 2019
AlphaBiomics at the 3rd Microbiome Movement – Drug Development Summit Europe 2019
We just arrived in Paris to attend the third edition of the Microbiome Movement conference series. This year’s focus is on discovering, developing, and delivering the next generation of microbiome-based therapeutic and diagnostic candidates to market.
November 5, 2018
AlphaBiomics wins the European QuickFire Challenge of Johnson & Johnson Innovation
As the winner of the European Innovation QuickFire Challenge, AlphaBiomics will receive €100,000 in grant funding to further advance its solutions in human healthcare as well as a voucher for one year of residency at an available JLABS location. Read more at Johnson & Johnson Innovation